Regeneron Pharmaceuticals, Inc. (REGN)

Over the past six months, Regeneron Pharmaceuticals' stock (REGN) has increased in price. As of April 10, 2026, the stock had surged 36% over the past six months, with a 52-week range from $476.49 to $821.11. On April 2, 2026, the closing share price was $761.85. Recent analyst activity includes Morgan Stanley maintaining an Equal-Weight rating, Bernstein maintaining an Outperform rating, Truist Securities maintaining a Buy rating, Piper Sandler announcing an Overweight rating, and Barclays initiating coverage with an Overweight rating. Regeneron announced an expected acquired in-process research and development (IPR&D) charge of approximately $102 million for the first quarter of 2026.

The pharmaceutical and biotech industry can exhibit seasonal patterns in demand for certain drugs, such as increased demand for flu medication in the winter and hay fever medication in the spring. These trends are more pronounced in the U.S. due to less restricted advertising compared to Europe. High-quality brands tend to achieve peak sales earlier and sustain these periods of high volume sales for longer. The publication of clinical studies can also significantly influence sales. Specific demand seasonality for Regeneron's individual products and services aligns with the therapeutic areas they address.

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases globally, operating within the Healthcare sector and Biotechnology industry. The company develops treatments for various conditions, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, hematologic conditions, and rare diseases. Its portfolio includes EYLEA and EYLEA HD for eye conditions, Dupixent for allergic and inflammatory diseases, Libtayo for cancer, Praluent for lowering LDL cholesterol, Kevzara for rheumatoid arthritis, Evkeeza, Inmazeb, ARCALYST for autoinflammatory conditions, ZALTRAP for metastatic colorectal cancer, and REGEN-COV for COVID-19. Regeneron partners with companies like Sanofi and Bayer and utilizes technologies like VelociSuite to identify drug targets and generate fully human antibodies.

Regeneron Pharmaceuticals Inc. operates primarily in the United States and the Rest of the World. In 2025, the United States accounted for approximately 91.8% of its total net product sales, while the Rest of the World accounted for approximately 8.2%. Key geographic areas include North America, Europe, and Asia.

Regeneron has a strong scientific reputation, known for its internally driven research model and disciplined approach to capital allocation. In 2019, the company was added to the Dow Jones Sustainability World Index, and it renewed its sponsorship of the Regeneron Science Talent Search through 2036. However, the company has faced scrutiny regarding executive compensation and a deal with BARDA, where the U.S. government funded 80% of the costs for Regeneron to develop and manufacture antibody-based medications, while Regeneron retained the right to set prices and control production.

Regeneron Pharmaceuticals' shareholder base is primarily led by major institutional investors, which collectively hold a significant portion of the company's stock. As of April 9, 2026, 1391 institutional owners and shareholders held a total of 87,204,048 shares. Institutional investors own 78% of Regeneron's shares, while retail investors and insiders own about 22%. Major institutional owners include The Vanguard Group, Inc., BlackRock Institutional Trust Company, N.A., State Street Investment Management (US), Dodge & Cox, JP Morgan Asset Management, and Geode Capital Management, LLC. Sanofi is the largest individual shareholder, owning 36.52 million shares, representing 34.54% of the company. Key insiders, including CEO Leonard S. Schleifer and CSO George D. Yancopoulos, have also engaged in recent insider trades.